Consumption of Diet Soda Sweetened with Sucralose and Acesulfame-Potassium Alters Inflammatory Transcriptome Pathways in Females with Overweight and Obesity.
Consumption of Diet Soda Sweetened with Sucralose and Acesulfame-Potassium Alters Inflammatory Transcriptome Pathways in Females with Overweight and Obesity.
复制标题
食用添加了三氯蔗糖和安赛蜜的无糖汽水会改变超重和肥胖女性的炎症转录组通路。
DOI：
10.1002/mnfr.201901166
复制
发表时间：
2020
影响因子：
5.2
通讯作者：
Hubal,MonicaJ
中科院分区：
文献类型：
--
作者：
Sylvetsky,AllisonC;Sen,Sabyasachi;Merkel,Patrick;Dore,Fiona;Stern,DavidB;Henry,CurtisJ;Cai,Hongyi;Walter,PeterJ;Crandall,KeithA;Rother,KristinaI;Hubal,MonicaJ
ScopeLow‐calorie sweetener (LCS) consumption is associated with metabolic disease in observational studies. However, physiologic mechanisms underlying LCS‐induced metabolic impairments in humans are unclear. This study is aimed at identifying molecular pathways in adipose impacted by LCSs.Methods and resultsSeven females with overweight or obesity, who did not report LCS use, consumed 12 ounces of diet soda containing sucralose and acesulfame‐potassium (Ace‐K) three times daily for 8 weeks. A subcutaneous adipose biopsy from the left abdomen and a fasting blood sample were collected at baseline and post‐intervention. Global gene expression were assessed using RNA‐sequencing followed by functional pathway analysis. No differences in circulating metabolic or inflammatory biomarkers were observed. However, ANOVA detected 828 differentially expressed annotated genes after diet soda consumption (p< 0.05), including transcripts for inflammatory cytokines. Fifty‐eight of 140 canonical pathways represented in pathway analyses regulated inflammation, and several key upstream regulators of inflammation (e.g., TNF‐alpha) were also represented.ConclusionConsumption of diet soda with sucralose and Ace‐K alters inflammatory transcriptomic pathways (e.g., NF‐κB signaling) in subcutaneous adipose tissue but does not significantly alter circulating biomarkers. Findings highlight the need to examine molecular and metabolic effects of LCS exposure in a larger randomized control trial for a longer duration.
